Company intelligence / Profile preview
Dantari
Thousand Oaks, California, United Statesdantari.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Dantari’s lead program, DAN‑222, is in early clinical trials for metastatic HER2-negative breast cancer. The company’s T-HDC platform enables a higher drug-to-antibody ratio and tunable payload release, aiming to improve efficacy and reduce side effects compared to standard chemotherapies. Other programs are in preclinical development targeting breast and prostate cancers.[5][6]
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025. Technology licensed from Caltech.[4][5]
Beyond the preview
Go deeper on Dantari.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dantari.